Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of “Buy” by Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received a consensus rating of “Buy” from the twelve brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $67.70.

Several brokerages have recently commented on JANX. UBS Group started coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday. Scotiabank dropped their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a research report on Thursday, November 7th.

Insiders Place Their Bets

In related news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the sale, the insider now owns 7,000 shares of the company’s stock, valued at approximately $296,310. The trade was a 23.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the sale, the chief executive officer now directly owns 282,054 shares in the company, valued at $15,101,171.16. This trade represents a 8.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 420,610 shares of company stock valued at $19,288,666 in the last 90 days. 29.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds have recently modified their holdings of the stock. FMR LLC grew its stake in Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after buying an additional 47,075 shares in the last quarter. Janus Henderson Group PLC grew its stake in Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after buying an additional 721,563 shares in the last quarter. Vanguard Group Inc. grew its stake in Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares in the last quarter. Logos Global Management LP grew its stake in Janux Therapeutics by 400.0% in the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after buying an additional 600,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Janux Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after buying an additional 38,490 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

Shares of JANX opened at $48.82 on Tuesday. The stock has a 50-day moving average of $50.05 and a 200-day moving average of $45.83. The company has a market cap of $2.56 billion, a PE ratio of -41.73 and a beta of 3.52. Janux Therapeutics has a one year low of $7.79 and a one year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business’s revenue was down 82.6% on a year-over-year basis. Analysts expect that Janux Therapeutics will post -1.34 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.